These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 28626169)

  • 1. New Discriminant Method for Identifying the Aggressive Disease Phenotype of Non-alcoholic Fatty Liver Disease.
    Kawamura Y; Ikeda K; Arase Y; Fujiyama S; Hosaka T; Kobayashi M; Saitoh S; Sezaki H; Akuta N; Suzuki F; Suzuki Y; Kumada H
    Intern Med; 2017; 56(12):1459-1465. PubMed ID: 28626169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of PNPLA3 polymorphisms as risk factor for NAFLD and liver fibrosis in an admixed population.
    Mazo DF; Malta FM; Stefano JT; Salles APM; Gomes-Gouvea MS; Nastri ACS; Almeida JR; Pinho JRR; Carrilho FJ; Oliveira CP
    Ann Hepatol; 2019; 18(3):466-471. PubMed ID: 31054980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PNPLA3 genotype increases susceptibility of nonalcoholic steatohepatitis among obese patients with nonalcoholic fatty liver disease.
    Tai CM; Huang CK; Tu HP; Hwang JC; Chang CY; Yu ML
    Surg Obes Relat Dis; 2015; 11(4):888-94. PubMed ID: 25240529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationships between Genetic Variations of PNPLA3, TM6SF2 and Histological Features of Nonalcoholic Fatty Liver Disease in Japan.
    Akuta N; Kawamura Y; Arase Y; Suzuki F; Sezaki H; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Suzuki Y; Ikeda K; Kumada H
    Gut Liver; 2016 May; 10(3):437-45. PubMed ID: 26610348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of PNPLA3 and TLL1 polymorphism can predict advanced fibrosis in Japanese patients with nonalcoholic fatty liver disease.
    Seko Y; Yamaguchi K; Mizuno N; Okuda K; Takemura M; Taketani H; Hara T; Umemura A; Nishikawa T; Moriguchi M; Yasui K; Kamaguchi M; Nishioji K; Mochizuki N; Kobayashi M; Mori K; Tanaka S; Matsuura K; Tanaka Y; Itoh Y
    J Gastroenterol; 2018 Mar; 53(3):438-448. PubMed ID: 28744823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of PNPLA3 polymorphism on diagnostic performance of various noninvasive markers for diagnosing and staging nonalcoholic fatty liver disease.
    Liu WY; Zheng KI; Pan XY; Ma HL; Zhu PW; Wu XX; Rios RS; Targher G; Byrne CD; Wang XD; Chen YP; Zheng MH
    J Gastroenterol Hepatol; 2020 Jun; 35(6):1057-1064. PubMed ID: 31677195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between non-alcoholic steatohepatitis, PNPLA3 I148M genotype and bone mineral density in adolescents.
    Mosca A; Fintini D; Scorletti E; Cappa M; Paone L; Zicari AM; Nobili V; Byrne CD
    Liver Int; 2018 Dec; 38(12):2301-2308. PubMed ID: 30176114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Additive effects of PNPLA3 and TM6SF2 on the histological severity of non-alcoholic fatty liver disease.
    Koo BK; Joo SK; Kim D; Bae JM; Park JH; Kim JH; Kim W
    J Gastroenterol Hepatol; 2018 Jun; 33(6):1277-1285. PubMed ID: 29193269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic determinants of steatosis and fibrosis progression in paediatric non-alcoholic fatty liver disease.
    Hudert CA; Selinski S; Rudolph B; Bläker H; Loddenkemper C; Thielhorn R; Berndt N; Golka K; Cadenas C; Reinders J; Henning S; Bufler P; Jansen PLM; Holzhütter HG; Meierhofer D; Hengstler JG; Wiegand S
    Liver Int; 2019 Mar; 39(3):540-556. PubMed ID: 30444569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association of nonalcoholic fatty liver disease with genetic polymorphisms: a multicenter study.
    Uygun A; Ozturk K; Demirci H; Oztuna A; Eren F; Kozan S; Yilmaz Y; Kurt O; Turker T; Vatansever S; Alper E; Unsal B
    Eur J Gastroenterol Hepatol; 2017 Apr; 29(4):441-447. PubMed ID: 28253210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted-bisulfite sequence analysis of the methylation of CpG islands in genes encoding PNPLA3, SAMM50, and PARVB of patients with non-alcoholic fatty liver disease.
    Kitamoto T; Kitamoto A; Ogawa Y; Honda Y; Imajo K; Saito S; Yoneda M; Nakamura T; Nakajima A; Hotta K
    J Hepatol; 2015 Aug; 63(2):494-502. PubMed ID: 25776890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PNPLA3 Expression Is Related to Liver Steatosis in Morbidly Obese Women with Non-Alcoholic Fatty Liver Disease.
    Aragonès G; Auguet T; Armengol S; Berlanga A; Guiu-Jurado E; Aguilar C; Martínez S; Sabench F; Porras JA; Ruiz MD; Hernández M; Sirvent JJ; Del Castillo D; Richart C
    Int J Mol Sci; 2016 Apr; 17(5):. PubMed ID: 27128907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Attenuated effect of PNPLA3 on hepatic fibrosis by HSD17B13 in Japanese patients with non-alcoholic fatty liver disease.
    Seko Y; Yamaguchi K; Tochiki N; Yano K; Takahashi A; Okishio S; Kataoka S; Okuda K; Umemura A; Moriguchi M; Tanaka S; Mori K; Okanoue T; Itoh Y
    Liver Int; 2020 Jul; 40(7):1686-1692. PubMed ID: 32342668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. I148M variant of PNPLA3 increases the susceptibility to non-alcoholic fatty liver disease caused by obesity and metabolic disorders.
    Xia MF; Ling Y; Bian H; Lin HD; Yan HM; Chang XX; Li XM; Ma H; Wang D; Zhang LS; Wang SS; Wu BJ; He WY; Zhao NQ; Gao X
    Aliment Pharmacol Ther; 2016 Mar; 43(5):631-42. PubMed ID: 26765961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low hepatic copper content and PNPLA3 polymorphism in non-alcoholic fatty liver disease in patients without metabolic syndrome.
    Stättermayer AF; Traussnigg S; Aigner E; Kienbacher C; Huber-Schönauer U; Steindl-Munda P; Stadlmayr A; Wrba F; Trauner M; Datz C; Ferenci P
    J Trace Elem Med Biol; 2017 Jan; 39():100-107. PubMed ID: 27908400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The PNPLA3 rs738409 C > G polymorphism is associated with the risk of progression to cirrhosis in NAFLD patients.
    Vespasiani-Gentilucci U; Gallo P; Porcari A; Carotti S; Galati G; Piccioni L; De Vincentis A; Dell'Unto C; Vorini F; Morini S; Riva E; Picardi A
    Scand J Gastroenterol; 2016 Aug; 51(8):967-73. PubMed ID: 27150500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of mitochondrial genomics in patients with non-alcoholic steatohepatitis (NASH).
    Mehta R; Jeiran K; Koenig AB; Otgonsuren M; Goodman Z; Baranova A; Younossi Z
    BMC Med Genet; 2016 Sep; 17(1):63. PubMed ID: 27596100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of PNPLA3 Polymorphism with Hepatocellular Carcinoma Development and Prognosis in Viral and Non-Viral Chronic Liver Diseases.
    Khlaiphuengsin A; Kiatbumrung R; Payungporn S; Pinjaroen N; Tangkijvanich P
    Asian Pac J Cancer Prev; 2015; 16(18):8377-82. PubMed ID: 26745088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The common PNPLA3 variant p.I148M is associated with liver fat contents as quantified by controlled attenuation parameter (CAP).
    Arslanow A; Stokes CS; Weber SN; Grünhage F; Lammert F; Krawczyk M
    Liver Int; 2016 Mar; 36(3):418-26. PubMed ID: 26264356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.